Treatment De-escalation and Therapy Modification

Dr. Melody asks about therapy de-escalation in diffuse large B-cell lymphoma patients with rapid ctDNA clearance, contrasting this with standard guideline adherence. Dr. Roschewski affirms willingness to consider de-escalation in appropriate contexts, drawing from National Cancer Institute principles emphasizing excessive toxicity concerns and questioning 6-cycle necessity, which was established primarily by proving superiority over 8 cycles rather than experimental derivation.

Most patients achieve undetectable ctDNA after 2 cycles, particularly low-risk cases, suggesting cycles 4 to 6 may not contribute to cure. Historical precedent exists from Wyndham Wilson's work with patients who have HIV, who demonstrated heightened treatment sensitivity. This approach applies to current older patients or those with significant comorbidities. In that study, patients received 2 cycles of EPOCH-R, then 1 additional cycle if achieving good PET response, with mature data showing over 80% cure rates for 3-cycle regimens.

Low-risk disease patients represent another de-escalation candidate group, despite advanced staging systems extrapolated from Hodgkin lymphoma that do not reflect large-cell lymphoma biology. Although preferring clinical trial contexts for such approaches, forced decisions in low-risk disease with tolerance issues might justify earlier cessation. After 3 cycles, risk-benefit calculations shift toward limiting toxicity rather than maximizing treatment intensity.

This approach requires randomized studies for definitive validation but recognizes that 6-cycle standards were not experimentally derived. Dr. Melody agrees, interpreting this as increased confidence in treatment adequacy for patients unable to tolerate full regimens, knowing that under-treatment risks are minimized when both interim PET and ctDNA show negative results. The biological rationale supports this thinking despite standard-of-care deviations.